The FDA has granted Fast Track designation to PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.

The Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 (nabilone/gabapentin) for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.

while others like dronabinol or nabilone, are synthetic and only mimic CBD and THC. But this would be the first time a drug candidate of this kind is moving through the FDA process. “It's not ...

The anti-oxidants α-tocopherol and butylhydroxytoluene were unable to elicit the same neuroprotection as Δ9-THC. The antioxidant Δ9-THC analogue nabilone potentiated neurotoxicity induced by MPP+.

Two pharmaceutical cannabinoid products are approved by Health Canada, Sativex (pure THC/CBD extract) and nabilone (a synthetic CB1 agonist). The specific Health Canada labelled indications for these ...

Cannabis is the most commonly used illicit drug worldwide, with ~5 million daily users worldwide. Emerging evidence supports a number of associations between cannabis and psychosis/psychotic disorders ...

‘…acute psychotic reactions, generally lasting but a few hours, but occasionally as long as a week; the reaction seemed dose-related and its main features ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

I have been listing medical anniversaries annually since 2016, and have recently done so for 2025.1 For this purpose I have counted an anniversary as a date on which ...

Objective The objective of this study is to evaluate the comparative benefits and harms of opioids and cannabis for medical use for chronic non-cancer pain. Design Systematic review and network ...